Literature DB >> 22997344

Outcomes of male patients with Alport syndrome undergoing renal replacement therapy.

Johanna Temme1, Anneke Kramer, Kitty J Jager, Katharina Lange, Frederick Peters, Gerhard-Anton Müller, Reinhard Kramar, James G Heaf, Patrik Finne, Runolfur Palsson, Anna V Reisæter, Andries J Hoitsma, Wendy Metcalfe, Maurizio Postorino, Oscar Zurriaga, Julio P Santos, Pietro Ravani, Faical Jarraya, Enrico Verrina, Friedo W Dekker, Oliver Gross.   

Abstract

BACKGROUND AND OBJECTIVES: Patients with the hereditary disease Alport syndrome commonly require renal replacement therapy (RRT) in the second or third decade of life. This study compared age at onset of RRT, renal allograft, and patient survival in men with Alport syndrome receiving various forms of RRT (peritoneal dialysis, hemodialysis, or transplantation) with those of men with other renal diseases. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients with Alport syndrome receiving RRT identified from 14 registries in Europe were matched to patients with other renal diseases. A linear spline model was used to detect changes in the age at start of RRT over time. Kaplan-Meier method and Cox regression analysis were used to examine patient and graft survival.
RESULTS: Age at start of RRT among patients with Alport syndrome remained stable during the 1990s but increased by 6 years between 2000-2004 and 2005-2009. Survival of patients with Alport syndrome requiring dialysis or transplantation did not change between 1990 and 2009. However, patients with Alport syndrome had better renal graft and patient survival than matched controls. Numbers of living-donor transplantations were lower in patients with Alport syndrome than in matched controls.
CONCLUSIONS: These data suggest that kidney failure in patients with Alport syndrome is now being delayed compared with previous decades. These patients appear to have superior patient survival while undergoing dialysis and superior patient and graft survival after deceased-donor kidney transplantation compared with patients receiving RRT because of other causes of kidney failure.

Entities:  

Mesh:

Year:  2012        PMID: 22997344      PMCID: PMC3513741          DOI: 10.2215/CJN.02190312

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  26 in total

1.  Renal transplantation in Alport's syndrome. Personal experience in twelve patients.

Authors:  L Berardinelli; E Pozzoli; M Raiteri; R Canal; G Tonello; A Tarantino; A Vegeto
Journal:  Contrib Nephrol       Date:  1990       Impact factor: 1.580

Review 2.  Molecular genetics of basement membranes: the paradigm of Alport syndrome.

Authors:  C Antignac
Journal:  Kidney Int Suppl       Date:  1995-06       Impact factor: 10.545

3.  Evolution of glomerular basement membrane lesions in a male patient with Alport syndrome: ultrastructural and morphometric study.

Authors:  A M Cangiotti; A Sessa; M Meroni; R Montironi; M Ragaiolo; V Mambelli; S Cinti
Journal:  Nephrol Dial Transplant       Date:  1996-09       Impact factor: 5.992

4.  Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries.

Authors:  P C van Dijk; K J Jager; F de Charro; F Collart; R Cornet; F W Dekker; C Grönhagen-Riska; R Kramar; T Leivestad; K Simpson; J D Briggs
Journal:  Nephrol Dial Transplant       Date:  2001-06       Impact factor: 5.992

5.  Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations.

Authors:  Johanna Temme; Frederick Peters; Katharina Lange; Yves Pirson; Laurence Heidet; Roser Torra; Jean-Pierre Grunfeld; Manfred Weber; Christoph Licht; Gerhard-Anton Müller; Oliver Gross
Journal:  Kidney Int       Date:  2012-01-11       Impact factor: 10.612

6.  Relationship between underlying renal disease and renal transplantation outcome.

Authors:  A J Bleyer; L A Donaldson; M McIntosh; P L Adams
Journal:  Am J Kidney Dis       Date:  2001-06       Impact factor: 8.860

Review 7.  Treatment of Alport syndrome: beyond animal models.

Authors:  Oliver Gross; Clifford E Kashtan
Journal:  Kidney Int       Date:  2009-06-17       Impact factor: 10.612

8.  Novel COL4A4 splice defect and in-frame deletion in a large consanguine family as a genetic link between benign familial haematuria and autosomal Alport syndrome.

Authors:  Oliver Gross; Kai-Olaf Netzer; Romy Lambrecht; Stefan Seibold; Manfred Weber
Journal:  Nephrol Dial Transplant       Date:  2003-06       Impact factor: 5.992

9.  Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.

Authors:  Oliver Gross; Bogdan Beirowski; Marie-Louise Koepke; Jeannine Kuck; Michael Reiner; Klaus Addicks; Neil Smyth; Eckhard Schulze-Lohoff; Manfred Weber
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

10.  Abnormally thin glomerular basement membranes associated with hematuria, proteinuria or renal failure in adults.

Authors:  F E Dische; M J Weston; V Parsons
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

View more
  24 in total

Review 1.  Ocular features in Alport syndrome: pathogenesis and clinical significance.

Authors:  Judy Savige; Shivanand Sheth; Anita Leys; Anjali Nicholson; Heather G Mack; Deb Colville
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-03       Impact factor: 8.237

2.  Identification of microRNAs and their target genes in Alport syndrome using deep sequencing of iPSCs samples.

Authors:  Wen-biao Chen; Jian-rong Huang; Xiang-qi Yu; Xiao-cong Lin; Yong Dai
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

3.  Renal, auricular, and ocular outcomes of Alport syndrome and their current management.

Authors:  Yanqin Zhang; Jie Ding
Journal:  Pediatr Nephrol       Date:  2017-09-01       Impact factor: 3.714

4.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

5.  Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment.

Authors:  Yasar Caliskan; Brian Lee; Adrian Whelan; Fadee Abualrub; Krista L Lentine; Arksarapuk Jittirat
Journal:  Curr Transplant Rep       Date:  2022-03-16

Review 6.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

Review 7.  De novo glomerular diseases after renal transplantation.

Authors:  Claudio Ponticelli; Gabriella Moroni; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 8.237

8.  Primary causes of kidney disease and mortality in dialysis-dependent children.

Authors:  Yusuke Okuda; Melissa Soohoo; Kenji Ishikura; Ying Tang; Yoshitsugu Obi; Marciana Laster; Connie M Rhee; Elani Streja; Kamyar Kalantar-Zadeh
Journal:  Pediatr Nephrol       Date:  2020-02-04       Impact factor: 3.714

Review 9.  Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020.

Authors:  Clifford E Kashtan; Oliver Gross
Journal:  Pediatr Nephrol       Date:  2020-11-06       Impact factor: 3.714

Review 10.  Gender Differences in Diabetic Kidney Disease: Focus on Hormonal, Genetic and Clinical Factors.

Authors:  Annalisa Giandalia; Alfio Edoardo Giuffrida; Guido Gembillo; Domenico Cucinotta; Giovanni Squadrito; Domenico Santoro; Giuseppina T Russo
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.